213 related articles for article (PubMed ID: 19458603)
1. MRI-based characterization of vascular disruption by 5,6-dimethylxanthenone-acetic acid in gliomas.
Seshadri M; Ciesielski MJ
J Cereb Blood Flow Metab; 2009 Aug; 29(8):1373-82. PubMed ID: 19458603
[TBL] [Abstract][Full Text] [Related]
2. Bioluminescence and MR Imaging of the Safety and Efficacy of Vascular Disruption in Gliomas.
Folaron M; Seshadri M
Mol Imaging Biol; 2016 Dec; 18(6):860-869. PubMed ID: 27160251
[TBL] [Abstract][Full Text] [Related]
3. Efficacy against subcutaneous or intracranial murine GL261 gliomas in relation to the concentration of the vascular-disrupting agent, 5,6-dimethylxanthenone-4-acetic acid (DMXAA), in the brain and plasma.
Yung R; Seyfoddin V; Guise C; Tijono S; McGregor A; Connor B; Ching LM
Cancer Chemother Pharmacol; 2014 Mar; 73(3):639-49. PubMed ID: 24477604
[TBL] [Abstract][Full Text] [Related]
4. ELTD1, an effective anti-angiogenic target for gliomas: preclinical assessment in mouse GL261 and human G55 xenograft glioma models.
Ziegler J; Pody R; Coutinho de Souza P; Evans B; Saunders D; Smith N; Mallory S; Njoku C; Dong Y; Chen H; Dong J; Lerner M; Mian O; Tummala S; Battiste J; Fung KM; Wren JD; Towner RA
Neuro Oncol; 2017 Feb; 19(2):175-185. PubMed ID: 27416955
[TBL] [Abstract][Full Text] [Related]
5. Assessment of the early effects of 5,6-dimethylxanthenone-4-acetic acid using macromolecular contrast media-enhanced magnetic resonance imaging: ectopic versus orthotopic tumors.
Seshadri M; Bellnier DA; Cheney RT
Int J Radiat Oncol Biol Phys; 2008 Nov; 72(4):1198-207. PubMed ID: 18954713
[TBL] [Abstract][Full Text] [Related]
6. Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.
Ellis L; Shah P; Hammers H; Lehet K; Sotomayor P; Azabdaftari G; Seshadri M; Pili R
Mol Cancer Ther; 2012 Feb; 11(2):383-92. PubMed ID: 22084164
[TBL] [Abstract][Full Text] [Related]
7. Monitoring antivascular therapy in head and neck cancer xenografts using contrast-enhanced MR and US imaging.
Seshadri M; Sacadura NT; Coulthard T
Angiogenesis; 2011 Dec; 14(4):491-501. PubMed ID: 21901534
[TBL] [Abstract][Full Text] [Related]
8. Rat tumor response to the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid as measured by dynamic contrast-enhanced magnetic resonance imaging, plasma 5-hydroxyindoleacetic acid levels, and tumor necrosis.
McPhail LD; McIntyre DJ; Ludwig C; Kestell P; Griffiths JR; Kelland LR; Robinson SP
Neoplasia; 2006 Mar; 8(3):199-206. PubMed ID: 16611413
[TBL] [Abstract][Full Text] [Related]
9. Assessment of tumor response to the vascular disrupting agents 5,6-dimethylxanthenone-4-acetic acid or combretastatin-A4-phosphate by intrinsic susceptibility magnetic resonance imaging.
McPhail LD; Griffiths JR; Robinson SP
Int J Radiat Oncol Biol Phys; 2007 Nov; 69(4):1238-45. PubMed ID: 17967313
[TBL] [Abstract][Full Text] [Related]
10. Activity of the vascular-disrupting agent 5,6-dimethylxanthenone-4-acetic acid against human head and neck carcinoma xenografts.
Seshadri M; Mazurchuk R; Spernyak JA; Bhattacharya A; Rustum YM; Bellnier DA
Neoplasia; 2006 Jul; 8(7):534-42. PubMed ID: 16867215
[TBL] [Abstract][Full Text] [Related]
11. Inhibition of CYP4A by a novel flavonoid FLA-16 prolongs survival and normalizes tumor vasculature in glioma.
Wang C; Li Y; Chen H; Zhang J; Zhang J; Qin T; Duan C; Chen X; Liu Y; Zhou X; Yang J
Cancer Lett; 2017 Aug; 402():131-141. PubMed ID: 28602979
[TBL] [Abstract][Full Text] [Related]
12. DCE and DW-MRI monitoring of vascular disruption following VEGF-Trap treatment of a rat glioma model.
Hoff BA; Bhojani MS; Rudge J; Chenevert TL; Meyer CR; Galbán S; Johnson TD; Leopold JS; Rehemtulla A; Ross BD; Galbán CJ
NMR Biomed; 2012 Jul; 25(7):935-42. PubMed ID: 22190279
[TBL] [Abstract][Full Text] [Related]
13. The vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid improves the antitumor efficacy and shortens treatment time associated with Photochlor-sensitized photodynamic therapy in vivo.
Seshadri M; Bellnier DA
Photochem Photobiol; 2009; 85(1):50-6. PubMed ID: 18643909
[TBL] [Abstract][Full Text] [Related]
14. Magnetic resonance imaging-based detection of glial brain tumors in mice after antiangiogenic treatment.
Claes A; Gambarota G; Hamans B; van Tellingen O; Wesseling P; Maass C; Heerschap A; Leenders W
Int J Cancer; 2008 May; 122(9):1981-6. PubMed ID: 18081012
[TBL] [Abstract][Full Text] [Related]
15. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
16. A new anti-glioma therapy, AG119: pre-clinical assessment in a mouse GL261 glioma model.
Towner RA; Ihnat M; Saunders D; Bastian A; Smith N; Pavana RK; Gangjee A
BMC Cancer; 2015 Jul; 15():522. PubMed ID: 26177924
[TBL] [Abstract][Full Text] [Related]
17. Tumor vascular response to photodynamic therapy and the antivascular agent 5,6-dimethylxanthenone-4-acetic acid: implications for combination therapy.
Seshadri M; Spernyak JA; Mazurchuk R; Camacho SH; Oseroff AR; Cheney RT; Bellnier DA
Clin Cancer Res; 2005 Jun; 11(11):4241-50. PubMed ID: 15930363
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of anti-tumor activity by low-dose combination of the recombinant urokinase kringle domain and celecoxib in a glioma model.
Kim CK; Joe YA; Lee SK; Kim EK; O E; Kim HK; Oh BJ; Hong SH; Hong YK
Cancer Lett; 2010 Feb; 288(2):251-60. PubMed ID: 19664879
[TBL] [Abstract][Full Text] [Related]
19. Effects of the nitric oxide donor JS-K on the blood-tumor barrier and on orthotopic U87 rat gliomas assessed by MRI.
Weidensteiner C; Reichardt W; Shami PJ; Saavedra JE; Keefer LK; Baumer B; Werres A; Jasinski R; Osterberg N; Weyerbrock A
Nitric Oxide; 2013 Apr; 30():17-25. PubMed ID: 23370169
[TBL] [Abstract][Full Text] [Related]
20. Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors.
Folkins C; Man S; Xu P; Shaked Y; Hicklin DJ; Kerbel RS
Cancer Res; 2007 Apr; 67(8):3560-4. PubMed ID: 17440065
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
